Pages that link to "Q37869193"

The following pages link to Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease. (Q37869193):

Displaying 21 items.

• Effects of anti-tumor necrosis factor α agents on bone (Q26851274) (← links)
• Review article: vitamin D and inflammatory bowel disease--established concepts and future directions (Q27015639) (← links)
• Improvements in Bone Density and Structure during Anti-TNF-α Therapy in Pediatric Crohn's Disease (Q30300036) (← links)
• Osteoblast Role in Rheumatic Diseases. (Q33838967) (← links)
• Bone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases (Q35614331) (← links)
• Growth and bone health in paediatric patients with Crohn's disease receiving subcutaneous tumor necrosis factor antibody (Q35692293) (← links)
• Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases (Q36781280) (← links)
• Inflammatory bone loss: pathogenesis and therapeutic intervention (Q37989394) (← links)
• Changes of the cytokine profile in inflammatory bowel diseases (Q38058782) (← links)
• Bone marrow Th17 TNFα cells induce osteoclast differentiation and link bone destruction to IBD. (Q41665502) (← links)
• The RhoGAP activity of myosin IXB is critical for osteoclast podosome patterning, motility, and resorptive capacity (Q41888788) (← links)
• Endocrine and metabolic manifestations in inflammatory bowel disease (Q42406756) (← links)
• Bone mineral density and inflammatory bowel disease severity (Q42664538) (← links)
• Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation (Q46227890) (← links)
• Re-evaluating osteoporosis and fracture risk in Crohn's disease patients in the era of TNF-alpha inhibitors (Q47174371) (← links)
• Opportunistic screening for bone disease using abdominal CT scans obtained for other reasons in newly diagnosed IBD patients. (Q52665445) (← links)
• Musculoskeletal system in children and adolescents with inflammatory bowel disease: normal muscle force, decreased trabecular bone mineral density and low prevalence of vertebral fractures. (Q53096952) (← links)
• The Role of Osteocytes in Inflammatory Bone Loss (Q64268866) (← links)
• Vitamin D deficiency and corticosteroid use are risk factors for low bone mineral density in inflammatory bowel disease patients (Q87424364) (← links)
• Perspective on skeletal health in inflammatory bowel disease (Q91856399) (← links)
• Bone alterations in inflammatory bowel diseases (Q92685563) (← links)